GEMINA LABS LTD Cash Flow Conversion Efficiency
GEMINA LABS LTD cash flow conversion efficiency. Based on the latest financial reports, GEMINA LABS LTD (8I7) has a cash flow conversion efficiency ratio of -0.007x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€34.61K ≈ $40.46K USD) by net assets (€-5.14 Million ≈ $-6.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GEMINA LABS LTD (2022–2025)
Cash flow conversion efficiency of GEMINA LABS LTD from 2022 to 2025. This chart illustrates how GEMINA LABS LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GEMINA LABS LTD (8I7) stock price for real-time trading data and today's change.
GEMINA LABS LTD Cash Flow Conversion Ratio Explained
GEMINA LABS LTD cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GEMINA LABS LTD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GEMINA LABS LTD ranked by their cash flow conversion efficiency. Also see GEMINA LABS LTD market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CanadaBis Capital Inc
V:CANB
|
0.056x |
|
Ranchero Gold Corp
V:RNCH
|
-1.403x |
|
Tarachi Gold Corp
F:4RZ
|
-0.031x |
|
SaverOne 2014 Ltd. American Depositary Shares
NASDAQ:SVRE
|
-0.340x |
|
Ngenic AB
ST:NGENIC
|
0.592x |
|
Edison Lithium Corp
V:EDDY
|
-1.162x |
|
Baker Steel Resources Trust
LSE:BSRT
|
-0.006x |
|
CBEYOND
F:C5B
|
0.724x |
Annual Cash Flow Conversion Efficiency for GEMINA LABS LTD (2022–2025)
The table below shows the annual cash flow conversion efficiency of GEMINA LABS LTD from 2022 to 2025. Review 8I7 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | €-4.44 Million ≈ $-5.19 Million |
€-1.30 Million ≈ $-1.52 Million |
0.293x | -85.66% |
| 2024-01-31 | €-1.59 Million ≈ $-1.85 Million |
€-3.24 Million ≈ $-3.79 Million |
2.046x | -96.74% |
| 2023-01-31 | €-71.81K ≈ $-83.95K |
€-4.51 Million ≈ $-5.27 Million |
62.798x | +1631.50% |
| 2022-01-31 | €944.23K ≈ $1.10 Million |
€-3.87 Million ≈ $-4.53 Million |
-4.100x | -- |
About GEMINA LABS LTD
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more